Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neihulizumab vs Conventional Treatment in Sr-aGvHD
NCT02694770Phase 2Withdrawn
- Sponsor
- AbGenomics
- Start
- Jul 2016
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of neihulizumab in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by AbGenomics. Primary endpoint: Overall Response Rate at 28 days. Planned start Jul 2016; status: withdrawn.
02
Drugs
neihulizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02694770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694770.